808 related articles for article (PubMed ID: 24423981)
1. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.
Pope HG; Wood RI; Rogol A; Nyberg F; Bowers L; Bhasin S
Endocr Rev; 2014 Jun; 35(3):341-75. PubMed ID: 24423981
[TBL] [Abstract][Full Text] [Related]
2. Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects.
Anderson LJ; Tamayose JM; Garcia JM
Mol Cell Endocrinol; 2018 Mar; 464():65-74. PubMed ID: 28606865
[TBL] [Abstract][Full Text] [Related]
3. Anabolic steroid use in adolescents: identification of those at risk and strategies for prevention.
Mulcahey MK; Schiller JR; Hulstyn MJ
Phys Sportsmed; 2010 Oct; 38(3):105-13. PubMed ID: 20959703
[TBL] [Abstract][Full Text] [Related]
4. Performance-enhancing drugs and the Olympics.
Watson CJ; Stone GL; Overbeek DL; Chiba T; Burns MM
J Intern Med; 2022 Feb; 291(2):181-196. PubMed ID: 35007384
[TBL] [Abstract][Full Text] [Related]
5. The Changing Drug Culture: Use and Misuse of Appearance- and Performance-Enhancing Drugs.
Albertson TE; Chenoweth JA; Colby DK; Sutter ME
FP Essent; 2016 Feb; 441():30-43. PubMed ID: 26881771
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence and Characteristics of Performance-Enhancing Drug Use Among Bodybuilding Athletes in the South of Iran, Bushehr.
Haerinejad MJ; Ostovar A; Farzaneh MR; Keshavarz M
Asian J Sports Med; 2016 Sep; 7(3):e35018. PubMed ID: 27826400
[TBL] [Abstract][Full Text] [Related]
7. Position stand on androgen and human growth hormone use.
Hoffman JR; Kraemer WJ; Bhasin S; Storer T; Ratamess NA; Haff GG; Willoughby DS; Rogol AD
J Strength Cond Res; 2009 Aug; 23(5 Suppl):S1-S59. PubMed ID: 19620932
[TBL] [Abstract][Full Text] [Related]
8. Doping in sport: effects, harm and misconceptions.
Birzniece V
Intern Med J; 2015 Mar; 45(3):239-48. PubMed ID: 25369881
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Management of Anabolic Androgenic Steroid Use.
Anawalt BD
J Clin Endocrinol Metab; 2019 Jul; 104(7):2490-2500. PubMed ID: 30753550
[TBL] [Abstract][Full Text] [Related]
10. Human growth hormone abuse in male weightlifters.
Brennan BP; Kanayama G; Hudson JI; Pope HG
Am J Addict; 2011; 20(1):9-13. PubMed ID: 21175915
[TBL] [Abstract][Full Text] [Related]
11. Harm Reduction in Male Patients Actively Using Anabolic Androgenic Steroids (AAS) and Performance-Enhancing Drugs (PEDs): a Review.
Bonnecaze AK; O'Connor T; Burns CA
J Gen Intern Med; 2021 Jul; 36(7):2055-2064. PubMed ID: 33948794
[TBL] [Abstract][Full Text] [Related]
12. [Cardiovascular alterations associated with doping].
Thieme D; Büttner A
Herz; 2015 May; 40(3):410-6. PubMed ID: 25828698
[TBL] [Abstract][Full Text] [Related]
13. Medical aspects of drug use in the gym.
Drug Ther Bull; 2004 Jan; 42(1):1-5. PubMed ID: 14768297
[TBL] [Abstract][Full Text] [Related]
14. The Health Threat Posed by the Hidden Epidemic of Anabolic Steroid Use and Body Image Disorders Among Young Men.
Goldman AL; Pope HG; Bhasin S
J Clin Endocrinol Metab; 2019 Apr; 104(4):1069-1074. PubMed ID: 30239802
[TBL] [Abstract][Full Text] [Related]
15. Ergogenic aids: a review of basic science, performance, side effects, and status in sports.
Tokish JM; Kocher MS; Hawkins RJ
Am J Sports Med; 2004 Sep; 32(6):1543-53. PubMed ID: 15310585
[TBL] [Abstract][Full Text] [Related]
16. Self-Reported Use and Attitudes Toward Performance-Enhancing Drugs in Ultramarathon Running.
Campian MD; Flis AE; Teramoto M; Cushman DM
Wilderness Environ Med; 2018 Sep; 29(3):330-337. PubMed ID: 30227921
[TBL] [Abstract][Full Text] [Related]
17. Potential health risks of foodborne performance-enhancing drugs in competitive sports.
Wei M; Wang J
Heliyon; 2023 Oct; 9(10):e21104. PubMed ID: 37916089
[TBL] [Abstract][Full Text] [Related]
18. Performance enhancing drug abuse and cardiovascular risk in athletes: implications for the clinician.
Angell PJ; Chester N; Sculthorpe N; Whyte G; George K; Somauroo J
Br J Sports Med; 2012 Nov; 46 Suppl 1():i78-84. PubMed ID: 23097484
[TBL] [Abstract][Full Text] [Related]
19. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk?
Tentori L; Graziani G
Pharmacol Res; 2007 May; 55(5):359-69. PubMed ID: 17349798
[TBL] [Abstract][Full Text] [Related]
20. Baseline characteristics of the HAARLEM study: 100 male amateur athletes using anabolic androgenic steroids.
Smit DL; de Hon O; Venhuis BJ; den Heijer M; de Ronde W
Scand J Med Sci Sports; 2020 Mar; 30(3):531-539. PubMed ID: 31663164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
